Cargando…

Suicide and Antidepressants: What Current Evidence Indicates

The documented efficacy and long-term benefit of antidepressants in patients with recurrent forms of severe anxiety or depressive disorders support their use in those individuals with these disorders, who experience suicidal thoughts or behavior. In general, it is assumed that antidepressants are be...

Descripción completa

Detalles Bibliográficos
Autores principales: Nischal, Anil, Tripathi, Adarsh, Nischal, Anuradha, Trivedi, J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353604/
https://www.ncbi.nlm.nih.gov/pubmed/22654381
http://dx.doi.org/10.4103/0973-1229.87287
_version_ 1782233075834421248
author Nischal, Anil
Tripathi, Adarsh
Nischal, Anuradha
Trivedi, J. K.
author_facet Nischal, Anil
Tripathi, Adarsh
Nischal, Anuradha
Trivedi, J. K.
author_sort Nischal, Anil
collection PubMed
description The documented efficacy and long-term benefit of antidepressants in patients with recurrent forms of severe anxiety or depressive disorders support their use in those individuals with these disorders, who experience suicidal thoughts or behavior. In general, it is assumed that antidepressants are beneficial for all symptoms of depression, including suicidality. However, some evidence suggests that Selective Serotonin Reuptake Inhibitors [SSRIs] may cause worsening of suicidal ideas in vulnerable patients. Systematic reviews and pooled analysis of experimental, observational, and epidemiological studies have investigated the use of SSRIs and their association with suicidality. Taking account of the methodological limitations of these studies, the current evidence fails to provide a clear relationship between their use and risk of suicidality in adults. However, in children and adolescents, there appears to be a bit of increased risk of suicidal ideations and attempts, but not of completed suicides. This risk can be anticipated and managed clinically. Clinicians are, therefore, advised to maintain a close follow-up during the initial treatment periods and remain vigilant of this risk. This advisory, however, should not deter clinicians from the use of effective dosages of antidepressants for a sufficient period of time, in every age group of patients, when clinically needed, and if found suitable otherwise.
format Online
Article
Text
id pubmed-3353604
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-33536042012-05-31 Suicide and Antidepressants: What Current Evidence Indicates Nischal, Anil Tripathi, Adarsh Nischal, Anuradha Trivedi, J. K. Mens Sana Monogr Review Article The documented efficacy and long-term benefit of antidepressants in patients with recurrent forms of severe anxiety or depressive disorders support their use in those individuals with these disorders, who experience suicidal thoughts or behavior. In general, it is assumed that antidepressants are beneficial for all symptoms of depression, including suicidality. However, some evidence suggests that Selective Serotonin Reuptake Inhibitors [SSRIs] may cause worsening of suicidal ideas in vulnerable patients. Systematic reviews and pooled analysis of experimental, observational, and epidemiological studies have investigated the use of SSRIs and their association with suicidality. Taking account of the methodological limitations of these studies, the current evidence fails to provide a clear relationship between their use and risk of suicidality in adults. However, in children and adolescents, there appears to be a bit of increased risk of suicidal ideations and attempts, but not of completed suicides. This risk can be anticipated and managed clinically. Clinicians are, therefore, advised to maintain a close follow-up during the initial treatment periods and remain vigilant of this risk. This advisory, however, should not deter clinicians from the use of effective dosages of antidepressants for a sufficient period of time, in every age group of patients, when clinically needed, and if found suitable otherwise. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3353604/ /pubmed/22654381 http://dx.doi.org/10.4103/0973-1229.87287 Text en Copyright: © Mens Sana Monographs http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nischal, Anil
Tripathi, Adarsh
Nischal, Anuradha
Trivedi, J. K.
Suicide and Antidepressants: What Current Evidence Indicates
title Suicide and Antidepressants: What Current Evidence Indicates
title_full Suicide and Antidepressants: What Current Evidence Indicates
title_fullStr Suicide and Antidepressants: What Current Evidence Indicates
title_full_unstemmed Suicide and Antidepressants: What Current Evidence Indicates
title_short Suicide and Antidepressants: What Current Evidence Indicates
title_sort suicide and antidepressants: what current evidence indicates
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353604/
https://www.ncbi.nlm.nih.gov/pubmed/22654381
http://dx.doi.org/10.4103/0973-1229.87287
work_keys_str_mv AT nischalanil suicideandantidepressantswhatcurrentevidenceindicates
AT tripathiadarsh suicideandantidepressantswhatcurrentevidenceindicates
AT nischalanuradha suicideandantidepressantswhatcurrentevidenceindicates
AT trivedijk suicideandantidepressantswhatcurrentevidenceindicates